ストックスクリーナーアプリを入手
14.59
9.99%
-1.62
前日終値:
$16.21
開ける：
$16.21
24時間の取引高:
262.32K
Relative Volume:
0.53
時価総額：
$666.05M
収益：
$1.42B
当期純損益:
$-140.69M
株価収益率:
-1.4982
EPS:
-9.7385
ネットキャッシュフロー:
$10.77M
1週間 パフォーマンス:
-18.92%
1か月 パフォーマンス:
-35.98%
6か月 パフォーマンス:
+2,994%
1年 パフォーマンス:
+2,994%
1日の値動き範囲:
$14.44
$16.30
1週間の範囲:
$14.44
$18.38
52週間の値動き範囲:
$0.4248
$28.00
Atento S.A. Ordinary Shares Stock (ATTO) Company Profile
Compare ATTO vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATTO
Atento S.A. Ordinary Shares
|
14.59 | 666.05M | 1.42B | -140.69M | 10.77M | -9.7385 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atento S.A. Ordinary Shares Stock (ATTO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-31 | 開始されました | Citigroup | Buy |
| 2026-08-31 | 開始されました | Leerink Partners | Outperform |
| 2026-08-31 | 開始されました | Morgan Stanley | Overweight |
| 2026-08-31 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-21 | アップグレード | Goldman | Sell → Neutral |
| 2020-04-30 | ダウングレード | Goldman | Neutral → Sell |
| 2019-06-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-01-07 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-08-21 | 繰り返されました | Barrington Research | Outperform |
| 2017-04-24 | 開始されました | Barrington Research | Outperform |
| 2016-05-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-03-09 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2014-11-11 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Atento S.A. Ordinary Shares (ATTO) 最新ニュース
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire
Goldman units trade Attovia Therapeutics (ATTO) shares, add swaps - Stock Titan
Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock - Stock Titan
Atento S.A. (OTC: ATTOF) Stock Price, News & Analysis - kalkine.ca
Goldman Sachs entities (NYSE: ATTO) report Attovia stock conversions and market-making trades - Stock Titan
Frazier Life Sciences XI Discloses Investment at Attovia Therapeutics with 13.5% Stake - tradingview.com
Frazier Life Sciences funds (ATTO) detail Attovia stakes and IPO purchases - Stock Titan
Attovia Therapeutics (ATTO) insider reports initial stock and option holdings - Stock Titan
Attovia Therapeutics (ATTO) major holder converts 18.2M preferred into common - Stock Titan
Attovia Therapeutics (ATTO) director discloses 72,792-share option grant and vesting terms - Stock Titan
ATTO SEC FilingsAttovia Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Attovia Therapeutics (ATTO) CMO Hubert Chen discloses stock and option positions - Stock Titan
Attovia Therapeutics (Nasdaq:ATTO)Stock Analysis - Simply Wall Street
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - finance.yahoo.com
Attovia Therapeutics Prices Upsized $289 Million Initial Public Offering - Quiver Quantitative
Attovia Therapeutics prices IPO at $17 per share on Nasdaq By Investing.com - Investing.com Nigeria
Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com India
Attovia Therapeutics prices upsized IPO at $17 per share - Investing.com
Attovia's 17M-share IPO is expected to begin Nasdaq Global Market trading Aug. 5 - Stock Titan
Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com
Redmile Group (ATTO) reports Series B preferred stake convertible into 782,854 shares - Stock Titan
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive
Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs - Seeking Alpha
Attovia Therapeutics Begins IPO Effort On Promising Early Trials (ATTO) - Seeking Alpha
Attovia Therapeutics files for IPO on Nasdaq - Investing.com
Attovia Therapeutics files for IPO on Nasdaq By Investing.com - Investing.com Nigeria
Atento SA stock (LU0992182062): Why Google Discover changes matter more now - AD HOC NEWS
Atento SA stock (LU0992182062): Why mobile-first delivery now matters more for customer experience i - AD HOC NEWS
Atento SA Stock (ISIN: LU0992182062) Faces Uncertainty Amid Sparse Market Activity - AD HOC NEWS
Attovia Therapeutics, Inc. (ATTO) Stock Price, News, Quote & History - Yahoo Finance
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Atento S.A. Ordinary Shares (ATTO) 財務データ
収益
当期純利益
現金流量
EPS
Atento S.A. Ordinary Shares (ATTO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| WALSH COLIN | Director |
Aug 06 '26 |
Buy |
17.00 |
500,000 |
8,500,000 |
3,020,632 |
| venBio Global Strategic Fund I | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
382,352 |
6,499,984 |
4,181,367 |
| Redmile Group, LLC | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
400,000 |
6,800,000 |
1,182,854 |
| Redmile Group, LLC | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
200,000 |
3,400,000 |
982,854 |
| Frazier Life Sciences XI, L.P. | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
588,235 |
9,999,995 |
6,154,213 |
| GOLDMAN SACHS GROUP INC | Former 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
500,000 |
8,500,000 |
3,020,632 |
| Sanofi | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
300,000 |
5,100,000 |
1,082,855 |
| WALSH COLIN | Director |
Aug 05 '26 |
Buy |
21.00 |
85,000 |
1,785,000 |
85,000 |
| WALSH COLIN | Director |
Aug 05 '26 |
Sale |
21.28 |
105,807 |
2,251,658 |
0 |
| GOLDMAN SACHS GROUP INC | Former 10% Owner |
Aug 05 '26 |
Buy |
21.00 |
85,000 |
1,785,000 |
85,000 |
0.61%
0.00%
大文字化:
|
ボリューム (24 時間):